These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 22374185)

  • 21. Gene polymorphisms in CCR5, CCR2, SDF1 and RANTES among Chinese Han population with HIV-1 infection.
    Li H; Liu TJ; Hong ZH
    Infect Genet Evol; 2014 Jun; 24():99-104. PubMed ID: 24650919
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alcohol dehydrogenase 3, glutathione S-transferase M1 and T1 polymorphisms, alcohol consumption and hepatocellular carcinoma (Italy).
    Covolo L; Gelatti U; Talamini R; Garte S; Trevisi P; Franceschi S; Franceschini M; Barbone F; Tagger A; Ribero ML; Parrinello G; Donadon V; Nardi G; Donato F
    Cancer Causes Control; 2005 Sep; 16(7):831-8. PubMed ID: 16132793
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Single nucleotide polymorphism of CC chemokine ligand 5 promoter gene in recipients may predict the risk of chronic graft-versus-host disease and its severity after allogeneic transplantation.
    Kim DH; Jung HD; Lee NY; Sohn SK
    Transplantation; 2007 Oct; 84(7):917-25. PubMed ID: 17984846
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlations of PD-L1 gene polymorphisms with susceptibility and prognosis in hepatocellular carcinoma in a Chinese Han population.
    Xie Q; Chen Z; Xia L; Zhao Q; Yu H; Yang Z
    Gene; 2018 Oct; 674():188-194. PubMed ID: 29940275
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of chemokine ligand 5/chemokine receptor 5 gene promoter polymorphisms with diabetic microvascular complications: A meta-analysis.
    Zhang Z; Zhang X; Dong J; Gao W; Liu F; Zhao J; Wu X; Guan X; Liu J; Liao L
    J Diabetes Investig; 2016 Mar; 7(2):212-8. PubMed ID: 27042273
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic variants in CCL5 and CCR5 genes and serum VEGF-A levels predict efficacy of bevacizumab in metastatic colorectal cancer patients.
    Suenaga M; Cao S; Zhang W; Yang D; Ning Y; Okazaki S; Berger MD; Miyamoto Y; Schirripa M; Soni S; Barzi A; Yamaguchi T; Lenz HJ
    Int J Cancer; 2019 May; 144(10):2567-2577. PubMed ID: 30411783
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic polymorphisms of tobacco- and alcohol-related metabolizing enzymes and the risk of hepatocellular carcinoma.
    Munaka M; Kohshi K; Kawamoto T; Takasawa S; Nagata N; Itoh H; Oda S; Katoh T
    J Cancer Res Clin Oncol; 2003 Jun; 129(6):355-60. PubMed ID: 12759747
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic variants of XRCC1 and risk of hepatocellular carcinoma in chronic hepatitis C patients.
    Arafa M; Besheer T; El-Eraky AM; Abo El-Khair SM; Elsamanoudy AZ
    Br J Biomed Sci; 2019 Apr; 76(2):64-69. PubMed ID: 31025604
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma.
    Marrero JA; Fontana RJ; Fu S; Conjeevaram HS; Su GL; Lok AS
    J Hepatol; 2005 Feb; 42(2):218-24. PubMed ID: 15664247
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MicroRNA gene polymorphisms and environmental factors increase patient susceptibility to hepatocellular carcinoma.
    Chu YH; Hsieh MJ; Chiou HL; Liou YS; Yang CC; Yang SF; Kuo WH
    PLoS One; 2014; 9(2):e89930. PubMed ID: 24587132
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A functional polymorphism in pre-microRNA-196a-2 contributes to the susceptibility of hepatocellular carcinoma in a Turkish population: a case-control study.
    Akkız H; Bayram S; Bekar A; Akgöllü E; Ulger Y
    J Viral Hepat; 2011 Jul; 18(7):e399-407. PubMed ID: 21692953
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IL17A gene polymorphism, serum IL17 and total IgE in Egyptian population with chronic HCV and hepatocellular carcinoma.
    ELBassuoni MA; Abd El Fatah G; Zaghla H
    Immunol Lett; 2015 Dec; 168(2):240-5. PubMed ID: 26367076
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Functional polymorphisms of cyclooxygenase-2 gene and risk for hepatocellular carcinoma.
    Akkız H; Bayram S; Bekar A; Akgöllü E; Ülger Y
    Mol Cell Biochem; 2011 Jan; 347(1-2):201-8. PubMed ID: 21042835
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Polymorphisms of the CYP1B1 gene and hepatocellular carcinoma risk in a Chinese population.
    Liu F; Luo LM; Wei YG; Li B; Wang WT; Wen TF; Yang JY; Xu MQ; Yan LN
    Gene; 2015 Jun; 564(1):14-20. PubMed ID: 25796598
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib.
    Suenaga M; Schirripa M; Cao S; Zhang W; Yang D; Ning Y; Cremolini C; Antoniotti C; Borelli B; Mashima T; Okazaki S; Berger MD; Miyamoto Y; Gopez R; Barzi A; Lonardi S; Yamaguchi T; Falcone A; Loupakis F; Lenz HJ
    Clin Colorectal Cancer; 2018 Jun; 17(2):e395-e414. PubMed ID: 29606345
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of MMP14 gene polymorphisms in susceptibility and pathological development to hepatocellular carcinoma.
    Chen TY; Li YC; Liu YF; Tsai CM; Hsieh YH; Lin CW; Yang SF; Weng CJ
    Ann Surg Oncol; 2011 Aug; 18(8):2348-56. PubMed ID: 21298348
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Functional role of CCL5/RANTES for HCC progression during chronic liver disease.
    Mohs A; Kuttkat N; Reißing J; Zimmermann HW; Sonntag R; Proudfoot A; Youssef SA; de Bruin A; Cubero FJ; Trautwein C
    J Hepatol; 2017 Apr; 66(4):743-753. PubMed ID: 28011329
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association between the Genetic Polymorphisms of
    Shao LN; Zhou SH; Wang N; Zhang ST; Liu M
    Immunol Invest; 2022 Jul; 51(5):1182-1197. PubMed ID: 33902378
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inflammation, genetic polymorphisms in proinflammatory genes TNF-A, RANTES, and CCR5, and risk of pancreatic adenocarcinoma.
    Duell EJ; Casella DP; Burk RD; Kelsey KT; Holly EA
    Cancer Epidemiol Biomarkers Prev; 2006 Apr; 15(4):726-31. PubMed ID: 16614115
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessment of frequencies of lifestyle factors and polymorphisms of drug-metabolizing enzymes (NAT2, CYP2E1) in human hepatocellular carcinoma (HCC) patients in a department of surgical medicine--a pilot investigation.
    Farker K; Schotte U; Scheele J; Hoffmann A
    Int J Clin Pharmacol Ther; 2002 Mar; 40(3):120-4. PubMed ID: 11911601
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.